E-LIB Suche - Ergebnisse für: Vajjah, Pavan

1

Population Pharmacokinetics and Exposure‐Response for Dapir..:

Acharya, Chayan ; Magnusson, Mats O. ; Vajjah, Pavan..
The Journal of Clinical Pharmacology. 63 (2023) 4 - p. 435-444 , 2023

Link: https://doi.org/10.1002/..

2

Strategies for clinical dose optimization of T cell-engagin..:

Ball, Kathryn ; Dovedi, Simon J ; Vajjah, Pavan.
mAbs. 15 (2023) 1 - p. , 2023

Link: https://doi.org/10.1080/..

3

Bimekizumab, a Novel Humanized IgG1 Antibody That Neutraliz..:

Adams, Ralph ; Maroof, Asher ; Baker, Terry...
Frontiers in Immunology. 11 (2020) - p. , 2020

Link: https://doi.org/10.3389/..

4

Randomized study of the safety and pharmacodynamics of inha..:

Burgess, Gary ; Boyce, Malcolm ; Jones, Margaret...
EBioMedicine. 35 (2018) - p. 67-75 , 2018

Link: https://doi.org/10.1016/..

5

First‐in‐human randomized study of bimekizumab, a humanized..:

Glatt, Sophie ; Helmer, Eric ; Haier, Birgit...
British Journal of Clinical Pharmacology. 83 (2017) 5 - p. 991-1001 , 2017

Link: https://doi.org/10.1111/..

6

Does age affect gastric emptying time? A model‐based meta‐a..:

Bonner, Jennifer J. ; Vajjah, Pavan ; Abduljalil, Khaled...
Biopharmaceutics & Drug Disposition. 36 (2015) 4 - p. 245-257 , 2015

Link: https://doi.org/10.1002/..

7

Precision criteria to derive sample size when designing ped..:

Salem, Farzaneh ; Ogungbenro, Kayode ; Vajjah, Pavan...
The Journal of Clinical Pharmacology. 54 (2013) 3 - p. 311-317 , 2013

Link: https://doi.org/10.1002/..

8

A reduction in between subject variability is not mandatory..:

Lagishetty, Chakradhar V. ; Vajjah, Pavan ; Duffull, Stephen B.
Journal of Pharmacokinetics and Pharmacodynamics. 39 (2012) 4 - p. 383-392 , 2012

Link: https://doi.org/10.1007/..

9

Reply to the editor of Journal of Pharmacokinetics and Phar..:

Lagishetty, Chakradhar V. ; Vajjah, Pavan ; Duffull, Stephen B.
Journal of Pharmacokinetics and Pharmacodynamics. 39 (2012) 6 - p. 727-727 , 2012

Link: https://doi.org/10.1007/..

10

A generalisation of T‐optimality for discriminating between..:

Vajjah, Pavan ; Duffull, Stephen B
Pharmaceutical Statistics. 11 (2012) 6 - p. 503-510 , 2012

Link: https://doi.org/10.1002/..

11

Bimekizumab, a Novel Humanized IgG1 Antibody That Neutraliz..:

Adams, Ralph ; Maroof, Asher ; Baker, Terry...
info:eu-repo/semantics/altIdentifier/doi/10.3389/fimmu.2020.01894. , 2020

Link: https://ut3-toulouseinp...

12

Bimekizumab, a Novel Humanized IgG1 Antibody That Neutraliz..:

Adams, Ralph ; Maroof, Asher ; Baker, Terry...
info:eu-repo/semantics/altIdentifier/doi/10.3389/fimmu.2020.01894. , 2020

Link: https://ut3-toulouseinp...

13

Strategies for clinical dose optimization of T cell-engagin..:

Kathryn Ball ; Simon J Dovedi ; Pavan Vajjah.
https://www.tandfonline.com/doi/10.1080/19420862.2023.2181016. , 2023

Link: https://doi.org/10.1080/..

14

Data_Sheet_1_Bimekizumab, a Novel Humanized IgG1 Antibody T..:

Ralph Adams ; Asher Maroof ; Terry Baker...
doi:10.3389/fimmu.2020.01894.s001. , 2020

Link: https://doi.org/10.3389/..

15

Bimekizumab, a Novel Humanized IgG1 Antibody That Neutraliz..:

Ralph Adams ; Asher Maroof ; Terry Baker...
https://www.frontiersin.org/article/10.3389/fimmu.2020.01894/full. , 2020

Link: https://doi.org/10.3389/..